↓ Skip to main content

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib

Overview of attention for article published in Oncotarget, October 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

twitter
20 tweeters

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
16 Mendeley